1. Volume 18, Issue 6, Pages 667-674.e1 (November 2017)
Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement 
Álvaro Quintanal-Villalonga, Andrés Carranza-Carranza, Ricardo Meléndez, Irene Ferrer, Sonia Molina-Pinelo, Luis Paz-Ares 
Clinical Lung Cancer 
Volume 18, Issue 6, Pages e1 (November 2017)
DOI: /j.cllc
Copyright © 2017 The Author(s) Terms and Conditions

2. Figure 1
FGFR4-388Arg Variant Correlates With Higher MAPK Activation. Representative Images of IHC Staining for pAKT and pERK in FGFR4-388Gly (Gly) and -388Arg (Arg) Patients
Abbreviations: IHC = immunohistochemistry; MAPK = mitogen-activated protein kinase; pAKT = phosphorylated protein kinase B; pERK = phosphorylated extracellular signal–regulated kinase.
Clinical Lung Cancer  , e1DOI: ( /j.cllc )
Copyright © 2017 The Author(s) Terms and Conditions

3. Figure 2
Kaplan-Meier Survival Plots for Overall and Progression-Free Survival. FGFR4-388Arg Variant Correlates With Poorer Overall and Progression-free Survival in SCC Patients With Lymph Node Involvement. Kaplan-Meier Survival Plots Are Shown for Overall and Progression-free Survival in Entire SCC Cohort and in SCC Patients With Lymph Node Involvement
Abbreviations: Arg = FGFR4-388Arg; Gly = FGFR4-388Gly; SCC = squamous-cell carcinoma.
Clinical Lung Cancer  , e1DOI: ( /j.cllc )
Copyright © 2017 The Author(s) Terms and Conditions